Throughout the last three months, 10 analysts have evaluated Boston Scientific BSX, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Boston Scientific, presenting an average target of $63.8, a high estimate of $67.00, and a low estimate of $60.00. Surpassing the previous average price target of $60.67, the current average has increased by 5.16%.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Boston Scientific among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Maintains | Outperform | $67.00 | - |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $67.00 | $61.00 |
| Marie Thibault | BTIG | Maintains | Buy | $64.00 | $64.00 |
| Larry Biegelsen | Wells Fargo | Maintains | Overweight | $62.00 | $62.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $66.00 | $59.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $62.00 | $59.00 |
| Joshua Jennings | TD Cowen | Raises | Outperform | $65.00 | $58.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $61.00 | $58.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $64.00 | $60.00 |
| Mike Matson | Needham | Lowers | Buy | $60.00 | $65.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Boston Scientific. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
All You Need to Know About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Financial Insights: Boston Scientific
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Boston Scientific's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Boston Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.72%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.49%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
